Garabedian Christopher Nishan 4
4 · Landos Biopharma, Inc. · Filed May 24, 2023
Insider Transaction Report
Form 4
Garabedian Christopher Nishan
Director
Transactions
- Award
Stock Option (right to buy)
2023-05-23+18,000→ 18,000 totalExercise: $0.33Exp: 2033-05-22→ Common Stock (18,000 underlying)
Footnotes (1)
- [F1]The shares subject to this option will vest and become exercisable on May 23, 2024, subject to the Reporting Person providing continuous service through such date.